-
公开(公告)号:US11974506B2
公开(公告)日:2024-04-30
申请号:US17528366
申请日:2021-11-17
Applicant: NATIONAL TAIWAN UNIVERSITY , Academia Sinica
Inventor: Po-Hsun Wu , Ssu-Yen Huang , Chia-Ling Chien , Danru Qu
CPC classification number: H10N52/101 , H10N50/85
Abstract: A spin-orbit torque device is disclosed, which includes: a magnetic layer; and a non-magnetic layer adjacent to the magnetic layer and comprising a spin-Hall material, wherein the spin-Hall material comprises NixCu1-x alloy, and x is in a range from 0.4 to 0.8.
-
12.
公开(公告)号:US20240101602A1
公开(公告)日:2024-03-28
申请号:US18038592
申请日:2021-11-24
Applicant: ACADEMIA SINICA , NATIONAL TAIWAN UNIVERSITY
Inventor: Rita P.Y. Chen , Chiu-Ping CHENG , Chien-Chih YANG , Kung-Ta LEE , Ying-Lien CHEN , Li-Hang Hsu , Hsin-Liang CHEN , Sung CHEN
Abstract: Provided is a peptide and method in preventing or treating infections caused by a wide spectrum of pathogens, including bacteria and fungus in hosts such as plants and animals. Methods of preventing or treating plant diseases and infection in animals are also provided.
-
公开(公告)号:US20240043944A1
公开(公告)日:2024-02-08
申请号:US18268842
申请日:2021-12-20
Applicant: Chiaho SHIH , Chun-Che LIAO , Chih-Shin CHANG , ACADEMIA SINICA
Inventor: Chiaho SHIH , Chun-Che LIAO , Chih-Shin CHANG
IPC: C12Q1/70
CPC classification number: C12Q1/701 , C12Q2600/156
Abstract: A method of detecting severe disease-associated mutations in an enterovirus 71 (EV-A71), comprising: performing an assay on a test sample containing an EV-A71 genomic RNA, a fragment thereof or an amplicon thereof, or an EV-A71 VP1 protein or fragment thereof to detect one or more severe disease-associated mutations in the EV-A71 genomic RNA, the fragment thereof or the amplicon thereof, or the EV-A71 protein or fragment thereof, wherein the one or more mutations are selected from mutations at positions corresponding to 5′ UTR nucleotide positions C580, A707, and C709 in an EV-A71 5′ UTR nucleic acid sequence and at residues corresponding to A280 and E145 in an EV-A71 VP1 protein sequence.
-
公开(公告)号:US20240010669A1
公开(公告)日:2024-01-11
申请号:US18227782
申请日:2023-07-28
Applicant: Academia Sinica
Inventor: Chih-Cheng CHEN , Jim-Min FANG , Cheng-Han LEE , Jen-Yao CHANG
IPC: C07H19/16 , A61K47/55 , A61P29/00 , A61K31/7076 , A61K38/04
CPC classification number: C07H19/16 , A61K47/55 , A61P29/00 , A61K31/7076 , A61K38/046
Abstract: Compounds for use in prevention and/or treatment of pain are disclosed. The compounds are derived by conjugation of N6-(4-hydroxybenzyl)adenosine and analogous compounds with amino acids or peptides. In one embodiment of the invention, the compound is 5′-glycylcarbonyl-N6-(4-hydroxybenzyl)adenosine (I-a1). In another embodiment of the invention, the compound is 5′-deoxy-5′-(N′-glycylureido)-N6-(4-hydroxybenzyl)adenosine (I-d1). Also disclosed are methods of making and using the same.
-
公开(公告)号:US11866489B2
公开(公告)日:2024-01-09
申请号:US17342514
申请日:2021-06-08
Applicant: Academia Sinica
Inventor: Ruey-Bing Yang , Yuh-Charn Lin
IPC: C07K16/22 , A61K39/395 , C07K16/18 , A61P35/00 , A61K39/00
CPC classification number: C07K16/22 , A61K39/395 , A61P35/00 , C07K16/18 , A61K2039/505 , A61K2039/507 , C07K2317/24 , C07K2317/34 , C07K2317/73 , C07K2317/76
Abstract: An isolated anti-SCUBE2 antibody or a binding fragment thereof is disclosed. The anti-SCUBE2 antibody comprises an antigen binding region that specifically binds to a target domain located within SCUBE2 (SEQ ID NO: 66) and exhibits a property of inhibiting VEGF-induced angiogenesis. The target domain is selected from the group consisting of the EGF-like motifs 4 to 6 ranging from a.a. position 175 to 323, or the spacer region ranging from a.a. position 441 to 659, or the first cys-rich motif ranging from a.a. position 668 to 725 of SCUBE2 (SEQ ID NO: 66). The anti-SCUBE2 antibody or binding fragment thereof is for use in treating a disease associated with VEGF-induced angiogenesis, or for use in treating a tumor or inhibiting tumor angiogenesis and cancer cell growth in a subject in need thereof.
-
公开(公告)号:US11859237B2
公开(公告)日:2024-01-02
申请号:US16677767
申请日:2019-11-08
Applicant: Academia Sinica
Inventor: Chia-Fu Chou , Jia-Wei Yeh , Yii-Lih Lin
IPC: C12Q1/68 , B01L3/00 , G01N15/14 , G01N33/487 , G01N15/10 , G01N27/327
CPC classification number: C12Q1/68 , B01L3/50273 , G01N15/1404 , G01N33/487 , B01L2300/041 , B01L2300/047 , B01L2300/06 , B01L2400/0406 , G01N27/3272 , G01N2015/1006 , G01N2015/1493
Abstract: A method for sizing a DNA molecule is disclosed, which comprises the following steps of: providing a DNA sizing device, comprising: a cover substrate; a substrate disposed on the cover substrate and comprising a first hole and a second hole; and a first slit-like channel disposed between the cover substrate and the substrate, wherein two ends of the first slit-like channel respectively connects to the first hole and the second hole; loading a sample comprising a DNA molecule to the first slit-like channel through the first hole, wherein the DNA molecule moves in a direction from the first hole to the second hole; detecting and recording an intensity and an area of a distribution of the DNA molecule; and analyzing the intensity and the area to obtain the size of a DNA molecule.
-
公开(公告)号:US20230409951A1
公开(公告)日:2023-12-21
申请号:US18250648
申请日:2021-11-23
Applicant: Northeastern University , Academia Sinica , Temple University-Of The Commonwealth System Of Higher Education
Inventor: Jeng-Yuan Tsai , Jinbo Pan , Hsin Lin , Arun Bansil , Qimin Yan
CPC classification number: G06N10/40 , G06N10/20 , H01L29/66977 , H01L29/66984
Abstract: Anion antisite defects in monolayer Transition Metal Dichalcogenide (TMD) systems are here identified as two-dimen-sional solid-state defect qubits. The proposed antisites in these TMDs host paramagnetic triplet ground states with flexible level splitting. A viable transition loop between the triplet and singlet defect states is demonstrated, including optical excitations/relaxations and nonradiative decay paths for the antisites as qubits. A complete set of qubit operational processes, including initialization, manipulation, and readout, is delineated.
-
公开(公告)号:US11813326B2
公开(公告)日:2023-11-14
申请号:US16959758
申请日:2019-01-03
Applicant: ACADEMIA SINICA
Inventor: Che-Ming Jack Hu , Saborni Chattopadhyay
CPC classification number: A61K39/39 , A61K9/5153 , A61K2039/55561
Abstract: This disclosure provides treatment kit that are capable of modulating the immune response. The treatment kit may also be used enhance the immunogenicity of antigens released from cell debris. Also provided are methods of using the treatment kit.
-
公开(公告)号:US20230348566A1
公开(公告)日:2023-11-02
申请号:US18025637
申请日:2021-09-10
Applicant: Academia Sinica
Inventor: Chi-Ming LIANG , Jeng-Jer SHIEH , Chung-Hsuan CHEN , Shu-Mei LIANG
IPC: C07K14/765 , A61P35/00
CPC classification number: C07K14/765 , A61P35/00
Abstract: Re-folded human serum albumin (rfHSA) and use thereof for anti-tumor are disclosed. The rfHSA comprises the primary amino acid sequence of naive human serum albumin, in which the rfHSA in a solution is oval shape, not fibrillar, and the naive HSA is globular. The rfHSA is used for treating cancer or a tumor in a subject in need thereof The rfHSA may also be used as a reagent for detecting the presence of a cancer cell associated with integrin β1 or serine/threonine protein kinase Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) in a tumor sample or as a reagent for inhibiting phosphorylation of Akt and ERK 1/2 in a cancer cell sample. A cell lysate of a cancer cell treated with rfHSA, a vaccine composition comprising the cancer cell lysate, and use thereof are also disclosed. Also disclosed is a method tor preparing rfHSA.
-
公开(公告)号:US20230279080A1
公开(公告)日:2023-09-07
申请号:US18146873
申请日:2022-12-27
Applicant: ACADEMIA SINICA
Inventor: Kuo-I LIN , Chi-Huey WONG , Szu-Wen WANG , Yi-Hsuan CHANG
IPC: C07K16/10 , G01N33/569 , A61K45/06
CPC classification number: C07K16/10 , A61K45/06 , G01N33/56983 , C07K2317/31 , C07K2317/41 , C07K2317/92 , G01N2333/165 , G01N2469/10
Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that is specific for a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.
-
-
-
-
-
-
-
-
-